Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges
- PMID: 38938565
- PMCID: PMC11210172
- DOI: 10.3389/fimmu.2024.1252258
Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges
Abstract
This study discusses the importance of minimal residual disease (MRD) detection in acute myeloid leukemia (AML) patients using liquid biopsy and next-generation sequencing (NGS). AML prognosis is based on various factors, including genetic alterations. NGS has revealed the molecular complexity of AML and helped refine risk stratification and personalized therapies. The long-term survival rates for AML patients are low, and MRD assessment is crucial in predicting prognosis. Currently, the most common methods for MRD detection are flow cytometry and quantitative PCR, but NGS is being incorporated into clinical practice due to its ability to detect genomic aberrations in the majority of AML patients. Typically, bone marrow samples are used for MRD assessment, but using peripheral blood samples or liquid biopsies would be less invasive. Leukemia originates in the bone marrow, along with the cfDNA obtained from peripheral blood. This study aimed to assess the utility of cell-free DNA (cfDNA) from peripheral blood samples for MRD detection in AML patients. A cohort of 20 AML patients was analyzed using NGS, and a correlation between MRD assessment by cfDNA and circulating tumor cells (CTCs) in paired samples was observed. Furthermore, a higher tumor signal was detected in cfDNA compared to CTCs, indicating greater sensitivity. Challenges for the application of liquid biopsy in MRD assessment were discussed, including the selection of appropriate markers and the sensitivity of certain markers. This study emphasizes the potential of liquid biopsy using cfDNA for MRD detection in AML patients and highlights the need for further research in this area.
Keywords: AML; Leukaemia; MRD; NGS; liquid biopsy; multiparametric flow cytometry.
Copyright © 2024 Álvarez, Martín, Dorado, Colmenares, Rufián, Rodríguez, Giménez, Carneros, Sanchez, Carreño, Rapado, Heredia, Martínez-López, Barrio and Ayala.
Conflict of interest statement
Authors AM, SD, LR, MR, YH, and SB were employed by the company Altum Sequencing Co. RA, JM-L, and SB are equity shareholders of Altum Sequencing Co. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia.Ann Lab Med. 2023 Jul 1;43(4):328-336. doi: 10.3343/alm.2023.43.4.328. Epub 2023 Feb 24. Ann Lab Med. 2023. PMID: 36843401 Free PMC article.
-
Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.Int J Mol Sci. 2018 Nov 6;19(11):3492. doi: 10.3390/ijms19113492. Int J Mol Sci. 2018. PMID: 30404199 Free PMC article. Review.
-
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Blood. 2018 Oct 18;132(16):1703-1713. doi: 10.1182/blood-2018-02-829911. Epub 2018 Sep 6. Blood. 2018. PMID: 30190321 Free PMC article.
-
Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.Ann Hematol. 2018 Jul;97(7):1155-1167. doi: 10.1007/s00277-018-3330-9. Epub 2018 Apr 27. Ann Hematol. 2018. PMID: 29704019 Review.
-
Microfluidics for the detection of minimal residual disease in acute myeloid leukemia patients using circulating leukemic cells selected from blood.Analyst. 2016 Jan 21;141(2):640-51. doi: 10.1039/c5an01836f. Analyst. 2016. PMID: 26523411 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical